HC Wainwright Has Strong Outlook for ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued on Sunday, November 9th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($0.50) per share for the year, up from their previous forecast of ($0.51). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share. HC Wainwright also issued estimates for Aclaris Therapeutics’ Q4 2025 earnings at ($0.13) EPS, Q1 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.53) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aclaris Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $8.71.

Aclaris Therapeutics Price Performance

Shares of NASDAQ ACRS opened at $2.30 on Wednesday. The stock has a market capitalization of $249.19 million, a P/E ratio of -1.68 and a beta of 0.43. Aclaris Therapeutics has a one year low of $1.05 and a one year high of $5.17. The firm’s 50 day simple moving average is $2.06 and its two-hundred day simple moving average is $1.71.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The company had revenue of $3.30 million for the quarter, compared to analysts’ expectations of $1.59 million. Aclaris Therapeutics had a negative return on equity of 34.01% and a negative net margin of 802.03%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC boosted its position in Aclaris Therapeutics by 25.9% during the 1st quarter. Acadian Asset Management LLC now owns 2,195,191 shares of the biotechnology company’s stock valued at $3,355,000 after buying an additional 451,044 shares during the period. OMERS ADMINISTRATION Corp raised its stake in shares of Aclaris Therapeutics by 223.3% during the first quarter. OMERS ADMINISTRATION Corp now owns 175,900 shares of the biotechnology company’s stock valued at $269,000 after acquiring an additional 121,500 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Aclaris Therapeutics by 29.7% during the first quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company’s stock worth $851,000 after purchasing an additional 127,366 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Aclaris Therapeutics by 20.2% during the first quarter. HighTower Advisors LLC now owns 316,064 shares of the biotechnology company’s stock worth $484,000 after purchasing an additional 53,116 shares during the period. Finally, Decheng Capital LLC grew its stake in shares of Aclaris Therapeutics by 78.3% in the first quarter. Decheng Capital LLC now owns 4,041,736 shares of the biotechnology company’s stock worth $6,184,000 after purchasing an additional 1,775,069 shares during the last quarter. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.